Raynaud’s Ischemia Needs Urgent Care

BY BRUCE JANCIN
FROM A SYMPOSIUM SPONSORED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY

SNOWMASS, COLO. – Persistent pain and nonreversible digital discoloration in a patient with Raynaud’s phenomenon are indicators of critical ischemia constituting a medical emergency.

“Raynaud’s patients will often say, ‘My fingers are uncomfortable. I feel pins and needles.’ But when they say it actually hurts, you’re in trouble. Particularly if they say, ‘It hurts beyond my finger, it hurts in the palm of my hand and radiates up in my arm, I have to hang my hand off the edge of the bed to get relief; it’s worse at nighttime,’ then you’ve reached the point of critical ischemia and if you don’t react you’re going to have big trouble,” Dr. Fredrick M. Wigley said at the symposium.

Although pain is the key feature marking a critical ischemic event, nonreversible discoloration is another indication. Affected digits will have well-demarcated pale-blue areas, and upon pressing down and then releasing the finger, no blood reflow is seen, explained Dr. Wigley, professor of medicine and head of the scleroderma center at Johns Hopkins University, Baltimore.

In contrast, reversibility is the hallmark of uncomplicated Raynaud’s. One of the most common triggers is reaching into the frozen foods section at the supermarket. But 15 minutes after re-warming, the discoloration is reversed. Uncomplicated Raynaud’s involves all the digits; the thumb is less often involved than the fingers, but it is not spared.

An acute ischemic crisis requires urgent care. Dr. Wigley’s management approach begins with rest and warming of the affected hand, followed quickly by a local digital block. He injects 2% lidocaine into the web at the base of the affected finger, placing the needle tip close to the digital nerve. This brings immediate pain relief, and it lets him see whether acute vasodilation occurs in response to the injection, an encouraging finding.

If the patient isn’t already on oral vasodilator therapy with a long-acting oral calcium channel blocker, he starts amiodipine immediately. In an acute ischemic crisis, Dr. Wigley resorts to low-dose epoprostenol infused into a peripheral vein at 0.5-2.0 ng/kg per minute continuously for 3 or more days. To avoid hospitalization, he allows patients to undergo the prostacyclin infusions on an outpatient basis and go home at the end of each treatment day.

Although it’s not a well-studied intervention, 48 hours of anticoagulation with unfractionated heparin or low-molecular-weight heparin makes sense in a patient with acute, rapidly advancing digital ischemia who is at risk of losing a digit, he said.

Dr. Wigley disclosed that he has received consulting fees and/or research grants from Actelion, Amira, KineMed, MedImmune, Novartis, Orion, Pfizer, and United Therapeutics.

Predictors of Raynaud’s Progression ID’ed

BY BRUCE JANCIN
EXPERT ANALYSIS FROM A SYMPOSIUM SPONSORED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY

SNOWMASS, COLO. – Abnormal findings on nailfold capillary microscopy and the presence of scleroderma-specific autoantibodies in patients presenting with new-onset Raynaud’s phenomenon without overt connective tissue disease are powerful independent predictors of progression to definite scleroderma.

A landmark Canadian prospective study in 586 consecutive patients presenting with isolated Raynaud’s phenomenon showed that 13% of them developed scleroderma during 3,197 person-years of follow-up. Another 1% developed other connective tissue diseases. Fewer than 2% of those with normal nailfold capillaries and no scleroderma-specific autoantibodies went on to develop definite scleroderma during 15-20 years, and the majority who did progress to scleroderma did so within the first year or two, noted Dr. Fredrick M. Wigley.

In contrast, 80% of patients with both evidence of microvascular damage on nailfold microscopy together with one or more scleroderma-specific autoantibodies developed scleroderma. Two-thirds of patients with these baseline findings in the Université de Montreal study (Arthritis Rheum. 2008;58:3902-12) progressed to definite scleroderma within the first 5 years of follow-up, added Dr. Wigley, professor of medicine and director of the scleroderma center at Johns Hopkins University, Baltimore.

Raynaud’s patients with one or more scleroderma-specific autoantibodies but no nailfold capillary abnormalities had a 35% rate of progression to scleroderma, with 60% of cases being diagnosed within the first 5 years. Patients with nailfold capillary abnormalities but no scleroderma-specific autoantibodies had a 26% long-term rate of progression to scleroderma, with roughly 90% of cases occurring within 5 years.

Nailfold microscopy is a simple matter. It can be carried out using a drop of immersion oil and an ophthalmoscope set at diopter 40. The microvascular damage that portends subsequent definitive scleroderma follows a characteristic chronicologic sequence consisting of enlarged capillary loops, followed by capillary loss, and capillary telangiectasias, the rheumatologist explained.

The autoantibodies that proved predictive were anticentromere (anti-CENP-B) anti-TTH/To, anti-topoisomerase I, and anti-RNA polymerase III. The findings in the Canadian study, which was the first large prospective study of predictors of scleroderma in patients with Raynaud’s phenomenon, were remarkably consistent with those obtained earlier through a literature search by investigators at Dartmouth-Hitchcock Medical Center, Lebanon, N.H.

They analyzed 10 published articles including 639 patients with primary Raynaud’s phenomenon and determined that 13% of them developed a connective tissue disease during 2,531 person-years of follow-up, compared with 14% of patients in the Montreal study.

Scleroderma accounted for the great majority of the cases of connective tissue disease in the Dartmouth-Hitchcock analysis, he said.

Dr. Wigley declared that he receives consulting fees and/or research grants from Actelion, Amira, KineMed, MedImmune, Novartis, Orion, Pfizer, and United Therapeutics.